Dutch guidelines for diagnosis and therapy of proliferative lupus nephritis

Netherlands Journal of Medicine

Volumn 70, Issue 4, 2012, Pages 199-206

  van Tellingen, A ^a   Voskuyl, A E ^a   Vervloet, M G ^a   Bijl, M ^b   de Sevaux R G L ^c   Berger, S P ^d   Derksen, R H W M ^e   Berden, J H M ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Azathioprine; Cyclophosphamide; Mycophenolate mofetil; Proliferative lupus nephritis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIMALARIAL AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COMPLEMENT COMPONENT C3; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA ANTIBODY; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; VITAMIN D;

ADD ON THERAPY; ANTIPHOSPHOLIPID SYNDROME; ANTIPHOSPHOLIPID SYNDROME NEPHROPATHY; ARTICLE; BLOOD PRESSURE; CLINICAL PRACTICE; CORTICOSTEROID INDUCED OSTEOPOROSIS; CREATININE BLOOD LEVEL; DIET RESTRICTION; DISEASE CLASSIFICATION; DRUG MEGADOSE; HEMATURIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICAL SOCIETY; MORTALITY; NEPHROTIC SYNDROME; NETHERLANDS; PATIENT MONITORING; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PROLIFERATIVE LUPUS NEPHRITIS; PROTEIN RESTRICTION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REPEAT PROCEDURE; RETINA DISEASE; SMOKING CESSATION; SODIUM RESTRICTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

ANTIRHEUMATIC AGENTS; AZATHIOPRINE; BIOPSY; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; NETHERLANDS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; TREATMENT OUTCOME;

EID: 84862530107     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Berden JHM, Licht R, Bruggen MCJ, et al. Role of nucleosomes for induction of glomerular binding of auto-antibodies in lupus nephritis. Opin Nephrol Hypertens. 1999;8:299-306.
2. Berden JH. Lupus Nephritis. Kidney Int. 1997;52:538-58.
3. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15:308-18.
4. Austin HA. Clinical evaluation and monitoring of lupus kidney disease. Lupus. 1998;7:618-21.
5. Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999;10:413-24.
6. Bastian HM, Roseman JM, McGwin G Jr. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus. 2002;11:152-60.
7. Derksen RHWM, Hene RJ, Kater L. The long-term clinical outcome of 56 patients with biopsy-proven lupus nephritis followed at a single centre. Lupus. 1992;1:97-103.
8. Donadio JV, Hart GM, Bergstrath EJ, Holley KE. Prognostic determinants in lupus nephritis: a long-term clinic-pathologic study. Lupus. 1995;4:109-15.
9. Houssiau FA, Vasconcelos C, D'Cruz D. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69:61-4.
10. Appel GB, Cohen DJ, Pirani CL, Meltzer JI, Estes D. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med. 1987;83:877-85.
11. Austin HA III, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcome in severe lupus nephritis: contributions of clinical and histological data. Kidney Int. 1994;45:544-50.
12. Bertsias G, Ioannidis JPA, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics. Ann Rheum Dis. 2008;67:195-205.
13. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521-30.
14. Mahajan SK, Ordonez NG, Feitelson PJ, Lim VS, Spargo BH, Katz AI. Lupus nephropathy without clinical renal involvement. Medicine. 1977;56:493-500.
15. Faurschou M, Starklint H, Halberg P, Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheum. 2006;33:1563-9.
16. Contreras G, Pardo V, Cely C, et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus. 2005;14:890-5.
17. Gladman DD, Urowitz MB, Cole E, Ritchie S, Chang CH, Churg J. Kidney biopsy in SLE. I. A clinical-morphologic evaluation. Q J Med. 1989;73:1125-33.
18. Nossent JC, Henzen-Logmans SC, Vroom TM, Huysen V, Berden JH, Swaak AJ. Relation between serological data at the time of the biopsy and renal histology in lupus nephritis. Rheum Int. 1991;11:77-82.
19. Berden JHM, Assman KJM. Renal involvement in collagen vascular diseases and dysproteinemias. Atlas of Diseases of the kidney. Vol IV.1999. Blackwell Science. Editor S. Klahr.
20. Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum. 2004;50:2569-79.
21. Singh JA, Solomon DH, Dougados M, et al. Development of classification and response criteria for rheumatic diseases. Arthritis Rheum. 2006;55:348-52.
22. Bertsias G, Gordon C, Boumpas DT. Clinical trial in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future - the EULAR recommendations for the management of SLE and the use of end-points in clinical trials. Lupus. 2008;17:437-42.
23. Gordon C, Bertsias G, Ioannidis JPA, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus. Ann Rheum Dis. 2009;68:470-6.
24. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum. 1991;605-7.
25. Gourley MF, Austin III HA, Scott D, et al. Methylprednsiolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann Int Med. 1996;125:549-57.
26. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: Arthritis Rheum. 2004;50:3934-40.
27. Chen YE, Korbet SM, Katz RS, et al. Value of complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol. 2008;3:46-53.
28. Chan TM, Tse KC, Tang CS, Lai KN, Li FK. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone. Lupus. 2005;14:265-72.
29. Ioannidis JP, Boki KA, Katsorida ME, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophophamide. Kidney Int. 2000;57:258-64.
30. Austin HA III, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Eng J Med. 1986;314:614-9.
31. Boumpas DT, Astin III AH, Vaughan EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophophamide in severe lupus nephritis. Lancet. 1992;340:741-5
32. Boumpas DT, Austin HA III, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Int Med. 1993;119:366-9.
33. Petri M. Prospective study of systemic lupus erythematosus pregnancies. Lupus. 2004;13:688-9.
34. Bansal VK, Beto JA. Treatmnet of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis. 1997;29:193-9.
35. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis. The Euro-Lupus Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46:2121-31.
36. Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 2006;70:732-42.
37. Arends S, Grootscholten C, Derksen RHWM, et al. Long-term follow-up of a randomized controlled trial of azathioprine/methylprednisolone versus cyclophophamide in patients with proliferative lupus nephritis. Ann Rheum Dis. 2011, nov 29 (Epub ahead of print).
38. Gaubitz M, Schorat A, Schotte A, Kern P, Domschke W. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus. 1999;8:731-6.
39. Dooley MA, Cosio FG, Nachman PH, et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol. 1999;10:833-9.
40. Chan TM, Li FK, Tang CSO, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med. 2000;343:1156-62.
41. Chan TM, Tse K-C, Tang CS-O, et al. Long-term study of mycophenolate mofetil versus continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005;16:1076-84.
42. On LM, Hooi LS, Lim TO, et al. andomized controlles trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrol. 2005;10:504-10.
43. Hu W, Liu Z, Chen H, et al. Mycophenolate mofetil versus cyclophosphamide therapy for patients with proliferative lupus nephritis. Chin Med J. 2002;115:705-9.
44. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Eng J Med. 2005;353:2219-28.
45. Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR. Mycophenolate mofetil for induction therapy of lupus nephritis: a systemic review and meta-analysis. Clin J Am Soc Nephrol. 2007;2:968-75.
46. Zhu B, Chen N, Lin Y, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant. 2007;22:1933-42.
47. Naveneethan SD, Viswanathan G, Strippoli GF. Treatment options for proliferative lupus nephritis: an update of clinical trial evidence. Drugs. 2008;68:2095-2104.
48. Mak A, Cheak AAC, Tan JYS, Su HC, Ho RCM, Sing Lau C. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology. 2009;48:944-52.
49. Kamanamool N, McEvoy M, Attia J, Ingsathit A, Ngamjanyaporn P, Thakkinstian A. Efficacy and adverse events of mycophenolate mofetil versus cuclophosphamide for induction therapy of lupus nephritis. Systemic review and meta-analysis. Medicine. 2010;89:227-35.
50. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophophamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103-12.